Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Alpha 1-antitrypsin deficiency secondary prevention
Introduction
Overview
Overview
Secondary prevention strategies following alpha1-antitrypsin deficiency (AATD) includes advising the patient to avoid cigarette smoking. Smoking accelerates the progression of emphysema in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls. Pneumonia and annual influenza vaccines will help prevent respiratory infections in patients with alpha1-antitrypsin deficiency (AATD).The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with purulent sputum be treated with early antibiotic therapy. Prompt and effective treatment of infections may provide protection from additional lung injury from an influx of neutrophils into the alveolus.
Secondary Prevention
Secondary Prevention
Secondary prevention strategies following alpha1-antitrypsin deficiency (AATD) includes :[1][2]
- The most effective secondary prevention strategy for alpha1-antitrypsin deficiency (AATD) patient is to avoid cigarette smoking. Smoking accelerates the progression of emphysema in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls.
- Pneumonia and annual influenza vaccines will help prevent respiratory infections in patients with alpha1-antitrypsin deficiency (AATD).
- The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with purulent sputum be treated with early antibiotic therapy. Prompt and effective treatment of infections may provide protection from additional lung injury from an influx of neutrophils into the alveolus.
References
References
- ↑ Fregonese L, Stolk J (2008). “Hereditary alpha-1-antitrypsin deficiency and its clinical consequences”. Orphanet J Rare Dis. 3: 16. doi:10.1186/1750-1172-3-16. PMC 2441617. PMID 18565211.
- ↑ Abusriwil H, Stockley RA (2006). “Alpha-1-antitrypsin replacement therapy: current status”. Curr Opin Pulm Med. 12 (2): 125–31. doi:10.1097/01.mcp.0000208452.57854.c6. PMID 16456382.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]